SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Autologous, TCR

Will Ziopharm Ever be Able to Commercialize Their Cell Therapy Products? Continuing Delays for Ziopharm’s TCR-T Programs; TriArm's Joint Venture Eden BioCell Dissolved; Ziopharm Q3 2021 Earnings Call Summary

Here is a brief preview of this blast: On Monday, November 8, Ziopharm held their Q3 2021 earnings call (press release) highlighting that during H1 2022 they anticipate manufacturing therapies at their Houston, TX, clinical production unit (CPU), as well as dosing the first patient in their TCR-T Library program. Moreover, management announced that they have developed four additional TCRs and plan submitting an amended IND protocol within the next few months. Below, Celltelligence provides insights on Ziopharm’s continued program delays and collaboration failures, while discussing the company’s likelihood of successfully bringing a cell therapy product to market.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.